NTLAIntellia Therapeutics, Inc.

$2B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$13M+12.0% YoY

Gross Profit

-$85M-670.4% margin

Operating Income

-$112M-888.1% margin

Net Income

-$103M-818.1% margin

EPS (Diluted)

$-1.17

QoQ Revenue Growth

-7.1%

Cash Flow

Operating Cash Flow

-$109M

Free Cash Flow

-$113M

Stock-Based Comp.

$27M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$227M

Stockholders' Equity

$1.2B

Cash & Equivalents

$294M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$13M	$11M	+12.0%
Gross Profit	-$85M	-$122M	+30.6%
Operating Income	-$112M	-$144M	+22.4%
Net Income	-$103M	-$147M	+29.8%

NTLA Q1 2023 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena